Impact of elective resection on plasma TIMP‐1 levels in patients with colon cancer
- 27 June 2005
- journal article
- research article
- Published by Wiley in Colorectal Disease
- Vol. 8 (3), 168-172
- https://doi.org/10.1111/j.1463-1318.2005.00831.x
Abstract
Objective Pre‐ and post‐operative plasma tissue inhibitor of metalloproteinases‐1 (TIMP‐1) levels have a prognostic impact on patients with colorectal cancer. However, the surgical trauma may play an essential role in regulation of plasma TIMP‐1 levels, which in turn may influence subsequent TIMP‐1 measurements. Patients and methods Consecutively, 48 patients with colon cancer (CC) and 12 patients with nonmalignant colonic disease were randomised to undergo elective laparoscopically assisted or open resection followed by fast track recovery. Plasma samples were collected just before and 1, 2 and 6 h after skin incision, and 1, 2, 8 and 30 days after surgery. TIMP‐1 was determined concurrently in all samples by a validated ELISA method. Results Geometric mean preoperative TIMP‐1 level was 142 ng/ml (range 54–559 ng/ml) among CC patients compared with 106 ng/ml (range 64–167 ng/ml) among patients with nonmalignant diseases (P < 0.0001). TIMP‐1 levels were decreased significantly 2 h after skin incision compared to the preoperative levels returning to preoperative levels at 6 h. A highly significant (P < 0.0001) maximum level was observed 1 day after surgery and was decreasing to preoperative levels 30 days after surgery. Patients undergoing laparoscopically assisted or open resection had similar TIMP‐1 levels at each time point. Conclusions Major surgery has considerable impact on plasma TIMP‐1 levels. Intra‐ and post‐operative changes of plasma TIMP‐1 levels are independent of the surgical approach, and resection for CC does not lead to a significant decrease of plasma TIMP‐1 levels within 30 days postoperatively.Keywords
This publication has 19 references indexed in Scilit:
- Functional Recovery After Open Versus Laparoscopic Colonic ResectionAnnals of Surgery, 2005
- Adjuvant Therapy for Stage II Colon Cancer: A Systematic Review From the Cancer Care Ontario Program in Evidence-Based Care’s Gastrointestinal Cancer Disease Site GroupJournal of Clinical Oncology, 2004
- Tissue Inhibitor of Metalloproteinase 1 Activates Normal Human Granulocytes, Protects Them from Apoptosis, and Blocks Their Transmigration during InflammationInfection and Immunity, 2004
- Association between preoperative plasma levels of tissue inhibitor of metalloproteinases 1 and rectal cancer patient survivalEuropean Journal Of Cancer, 2004
- Anaesthesia, surgery, and challenges in postoperative recoveryThe Lancet, 2003
- Extracellular matrix remodelling: the role of matrix metalloproteinasesThe Journal of Pathology, 2003
- Levels of tissue inhibitor of metalloproteinases-1 in blood transfusion componentsScandinavian Journal of Clinical and Laboratory Investigation, 2002
- Standard Dose (Mayo Regimen) 5-Fluorouracil and Low Dose Folinic Acid: Prohibitive Toxicity?American Journal of Clinical Oncology, 2000
- Human Neutrophils Secrete Gelatinase B In Vitro and In Vivoin Response to Endotoxin and Proinflammatory MediatorsAmerican Journal of Respiratory Cell and Molecular Biology, 1999
- Longitudinal data analysis using generalized linear modelsBiometrika, 1986